TrialThe Journal of allergy and clinical immunology2018

Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.

Verena Niederberger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.